Incyte Corporation Company Profile (NASDAQ:INCY)

About Incyte Corporation

Incyte Corporation logoIncyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INCY
  • CUSIP: 45337C10
Key Metrics:
  • Previous Close: $131.21
  • 50 Day Moving Average: $119.00
  • 200 Day Moving Average: $98.84
  • 52-Week Range: $60.30 - $131.89
  • Trailing P/E Ratio: 242.98
  • Foreward P/E Ratio: 115.10
  • P/E Growth: 3.93
  • Market Cap: $24.85B
  • Outstanding Shares: 188,598,000
  • Beta: 0.78
  • Net Margins: 14.71%
  • Return on Equity: 50.38%
  • Return on Assets: 10.58%
  • Debt-to-Equity Ratio: 1.74%
  • Current Ratio: 3.69%
  • Quick Ratio: 3.67%
Additional Links:
Companies Related to Incyte Corporation:

Analyst Ratings

Consensus Ratings for Incyte Corporation (NASDAQ:INCY) (?)
Ratings Breakdown: 18 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $122.56 (6.59% downside)

Analysts' Ratings History for Incyte Corporation (NASDAQ:INCY)
DateFirmActionRatingPrice TargetDetails
2/21/2017Jefferies Group LLCReiterated RatingBuy$140.00View Rating Details
2/16/2017BMO Capital MarketsReiterated RatingOutperform$135.00 -> $149.00View Rating Details
2/16/2017J P Morgan Chase & CoReiterated RatingBuy$136.00View Rating Details
2/15/2017Royal Bank of CanadaBoost Price TargetOutperform$123.00 -> $138.00View Rating Details
2/14/2017RBC Capital MarketsReiterated RatingOutperform$123.00 -> $138.00View Rating Details
1/27/2017Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$116.00 -> $149.00View Rating Details
1/23/2017Credit Suisse GroupInitiated CoverageOutperform$137.00View Rating Details
1/19/2017Barclays PLCBoost Price TargetBuy$105.00 -> $135.00View Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00View Rating Details
1/12/2017Cowen and CompanyReiterated RatingOutperformView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00View Rating Details
9/28/2016Piper Jaffray CompaniesSet Price TargetBuy$99.00View Rating Details
9/29/2016Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$115.00View Rating Details
9/26/2016ArgusBoost Price TargetBuy$92.00 -> $98.00View Rating Details
8/5/2016SunTrust Banks, Inc.Initiated CoverageBuy$105.00View Rating Details
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details
5/19/2016Morgan StanleyReiterated RatingBuyView Rating Details
5/10/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
1/31/2016Bank of America CorpReiterated RatingBuy$145.00 -> $87.00View Rating Details
11/19/2015UBS AGReiterated RatingBuy$130.00View Rating Details
10/6/2015NomuraBoost Price TargetBuy$126.00 -> $146.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Incyte Corporation (NASDAQ:INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q416$0.13$0.05$324.90 million$326.00 millionViewListenView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.05)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.09)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3($0.06)$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214$0.05($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.17)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corporation (NASDAQ:INCY)
Current Year EPS Consensus Estimate: $0.62 EPS
Next Year EPS Consensus Estimate: $1.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.02$0.34$0.14
Q2 20164($0.06)$0.03($0.02)
Q3 20164($0.01)$0.04$0.02
Q4 20164($0.10)$0.26$0.10
Q1 20173($0.94)($0.51)($0.76)
Q2 20173$0.59$0.93$0.73
Q3 20173($0.07)$0.61$0.26
Q4 20173($0.02)$0.75$0.34
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corporation (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Incyte Corporation (NASDAQ:INCY)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 92.62%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Incyte Corporation (NASDAQ:INCY)
News IconUnusual Activity Sighted in Incyte Corporation (NASDAQ:INCY) Shares - Winfield Review (NASDAQ:INCY) - February 24 at 7:12 PM
News IconIncyte Corporation (NASDAQ:INCY) Sees The Needle Move on Volume - Winfield Review (NASDAQ:INCY) - February 24 at 7:12 PM logoIncyte, CBOE Holdings, Regency Centers to join S&P 500 - Incyte ... - Seeking Alpha (NASDAQ:INCY) - February 24 at 7:12 PM logoPharma company Incyte is moving to the S&P 500, and the stock is rallying (NASDAQ:INCY) - February 24 at 4:20 PM logoBetter Buy: Juno Therapeutics vs. Incyte (NASDAQ:INCY) - February 24 at 10:47 AM logoIncyte Corp. (INCY) Has Jumped To A New High After Added To S&P 500 (NASDAQ:INCY) - February 24 at 10:16 AM logoIncyte and UPenn Ink Cancer Research Deal (INCY) (NASDAQ:INCY) - February 24 at 10:16 AM logoIncyte, University of Pennsylvania In Cancer Deal (NASDAQ:INCY) - February 24 at 10:16 AM logoIncyte Is Undervalued - Cramer's Lightning Round (2/22/17) - Seeking Alpha (NASDAQ:INCY) - February 23 at 5:56 PM
News IconA Delaware drug-discovery company teams with Penn for new cancer treatments (NASDAQ:INCY) - February 23 at 5:56 PM logoIncyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania (NASDAQ:INCY) - February 23 at 5:56 PM logoBRIEF-Incyte Corp says entered into letter agreement with certain entities affiliated with Julian Baker - SEC filing (NASDAQ:INCY) - February 22 at 6:08 PM logoINCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, F (NASDAQ:INCY) - February 22 at 6:08 PM logoIncyte to Present at Upcoming Investor Conferences (NASDAQ:INCY) - February 22 at 6:08 PM logoAndreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences (NASDAQ:INCY) - February 22 at 6:08 PM logoINCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:INCY) - February 22 at 12:39 PM
News IconIncyte and General Hospital Raise Awareness for Rare Blood Cancers (NASDAQ:INCY) - February 20 at 5:22 PM logoIncyte: Many Strengths, Small EPS, So What's It Worth? - Seeking Alpha (NASDAQ:INCY) - February 18 at 5:19 PM logoINCYTE CORP Financials (NASDAQ:INCY) - February 18 at 5:19 PM
News IconIncyte Corporation (INCY) Rating Reiterated by BMO Capital Markets (NASDAQ:INCY) - February 17 at 5:30 PM
News IconHow Are Incyte Corporation (NASDAQ:INCY) EPS Outlook Changing For Q2 2017? (NASDAQ:INCY) - February 17 at 5:30 PM logoBiotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data (NASDAQ:INCY) - February 16 at 4:46 PM logoIncyte Corp. :INCY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 (NASDAQ:INCY) - February 16 at 4:46 PM logoIncyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook (NASDAQ:INCY) - February 16 at 4:46 PM logoSoftness in Incyte Should Be Short-Lived, if Our Quants Are Right (NASDAQ:INCY) - February 16 at 4:46 PM logoIncyte Corp. :INCY-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (NASDAQ:INCY) - February 16 at 4:46 PM
News IconSell-Side Analyst's Predictions: Marsh & McLennan Companies, Inc. (MMC), Incyte Corporation (INCY) - The USA Commerce (NASDAQ:INCY) - February 16 at 8:11 AM
News IconBuy or Sell? Average Brokerage Ratings on Incyte Corporation (INCY), Digital Realty Trust, Inc. (DLR) - StockNewsJournal (NASDAQ:INCY) - February 15 at 9:04 PM logoAdditional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated ... - PR Newswire (press release) (NASDAQ:INCY) - February 15 at 9:04 PM logoAdditional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo (NASDAQ:INCY) - February 15 at 9:04 PM logo5:58 pm Incyte and Eli Lilly and Company (LLY (NASDAQ:INCY) - February 15 at 9:04 PM logoIncyte Corporation Bottom Line Falls 84% In Q4 (NASDAQ:INCY) - February 15 at 5:21 AM logoINCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and Financial Condition (NASDAQ:INCY) - February 15 at 5:21 AM
News IconIncyte Corporation (INCY) Posts Earnings Results, Misses Expectations By $0.09 EPS (NASDAQ:INCY) - February 15 at 12:19 AM
News IconIncyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs (NASDAQ:INCY) - February 15 at 12:19 AM logoIncyte 4Q Net $9 Million or 5 Cents a Share (INCY) (NASDAQ:INCY) - February 15 at 12:19 AM
News IconStock Price of Incyte Corporation (INCY) Increases 1.13% (NASDAQ:INCY) - February 15 at 12:19 AM
News IconLtd. Raises Stake in Incyte Corporation (INCY) (NASDAQ:INCY) - February 15 at 12:19 AM
News IconThe Van ECK Associates Corp Has $25275000 Stake in Incyte Corporation (INCY) (NASDAQ:INCY) - February 15 at 12:19 AM logoIncyte Corporation 2016 Q4 - Results - Earnings Call Slides (NASDAQ:INCY) - February 15 at 12:19 AM
News IconIncyte Corporation (INCY) Releases Earnings Results, Misses Expectations By $-0.18 EPS (NASDAQ:INCY) - February 15 at 12:19 AM
News IconHow Have Incyte Corporation (INCY) Earnings Outlook Changed? (NASDAQ:INCY) - February 15 at 12:19 AM logoIncyte tops Street 4Q forecasts (NASDAQ:INCY) - February 15 at 12:19 AM logoEdited Transcript of INCY earnings conference call or presentation 14-Feb-17 3:00pm GMT (NASDAQ:INCY) - February 15 at 12:19 AM
News IconWhat are Analyst's Indicators for Royal Caribbean Cruises Ltd. (RCL), Incyte Corporation (INCY) - The USA Commerce (NASDAQ:INCY) - February 14 at 7:17 PM
News IconIncyte Corporation (INCY) Releases Earnings Results, Misses Expectations By $-0.18 EPS - Highland Mirror (NASDAQ:INCY) - February 14 at 7:17 PM logoAgenus Gets A Boost From Incyte Cash Infusion - Benzinga (NASDAQ:INCY) - February 14 at 7:17 PM logoIncyte Corporation Bottom Line Falls 84% In Q4 - Nasdaq (NASDAQ:INCY) - February 14 at 7:17 PM logoIncyte 4Q Earnings $9 Million or 5 Cents a Share (NASDAQ:INCY) - February 14 at 7:17 PM logoIncyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss (NASDAQ:INCY) - February 14 at 7:17 PM


What is Incyte Corporation's stock symbol?

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?

18 brokers have issued 1-year target prices for Incyte Corporation's stock. Their predictions range from $85.00 to $149.00. On average, they expect Incyte Corporation's share price to reach $122.56 in the next twelve months.

When will Incyte Corporation announce their earnings?

Incyte Corporation is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

What are analysts saying about Incyte Corporation stock?

Here are some recent quotes from research analysts about Incyte Corporation stock:

  • According to Zacks Investment Research, "Although Incyte’s fourth-quarter results were positive beating on both the top and bottom line, Incyte is highly dependent on the single product, Jakafi, for growth which has its inherent risks. In addition, Jakafi could face competition from generic products.  While we are positive on the company’s efforts to expand Jakafi’s label, any development/regulatory setback could pull down the stock significantly. Also, most of its pipeline candidates are in early-to-mid stages of development, and hence are expected to take time before being approved for use. Iclusig also faces intense competition. Approved treatments include Novartis’ Gleevec/Glivec, Bristol-Myers’ Sprycel and Pfizer’s Bosulif among others. On the other hand, shares of the company have outperformed that of the industry in the past one year." (2/17/2017)

  • Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)
  • Brean Capital analysts commented, "US Jakafi sales of $183.3 million and 1Q16 total revenue of $263.5 million were in line with consensus of $183.6 million and $264 million, respectively. Ex-US Jakafi royalties of $21.9 million was also in line with consensus of $22.3 million. Incyte reported GAAP EPS of $0.12, versus consensus of $0.20, largely due to the $35 million milestone paid to Eli Lilly for GvHD rights to ruxolitinib. More importantly, Incyte updated full-year 2016 Jakafi US sales guidance to a new range $815-830 million from $800-815 million in order to better capture continued momentum in Jakafi revenue, and provided additional revenue guidance of $25-30 million for newly inlicensed Iclusig. We are encouraged by the robust volume growth in Jakafi revenue during 1Q16, offset by typical higher gross-to-net adjustment in 1Q16 due to the Medicare Part D donut hole. Incyte announced the acquisition of Ariad’s EU operations and an exclusive license to develop and commercialize Iclusig in the EU and 22 other countries. Following its discontinuance of the ruxolitinib JANUS program in metastatic pancreatic cancer and other trials, we view it as wise to purchase an approved product adding immediate revenue as well as coming with additional market potential. Incyte currently has 14 molecules in clinical development against 11 targets." (5/10/2016)

Who owns Incyte Corporation stock?

Incyte Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (1.94%), State Street Corp (1.91%), Shelton Capital Management (1.91%), Franklin Resources Inc. (1.57%), FMR LLC (1.47%) and Brown Capital Management LLC (1.40%). Company insiders that own Incyte Corporation stock include Barry A Ariko, Barry P Flannelly, Eric H Siegel, James M Daly, Julian Baker, Laurent Chardonnet, Paul A Friedman, Paula J Swain, Reid M Huber, Richard S Levy and Yao Wenqing.

Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Credit Agricole S A, Sands Capital Management LLC, Janus Capital Management LLC, State Street Corp, Calamos Advisors LLC, RTW Investments LP and Oxford Asset Management. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, Paula J Swain and Reid M Huber.

Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?

Incyte Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Shelton Capital Management, Fred Alger Management Inc., Federated Investors Inc. PA, Viking Global Investors LP, Asset Management One Co. Ltd., Marshall Wace LLP, Franklin Resources Inc. and Frontier Capital Management Co. LLC.

How do I buy Incyte Corporation stock?

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Incyte Corporation stock cost?

One share of Incyte Corporation stock can currently be purchased for approximately $131.21.

Incyte Corporation (NASDAQ:INCY) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Earnings History Chart

Earnings by Quarter for Incyte Corporation (NASDAQ:INCY)

Dividend History Chart

Dividend Payments by Quarter for Incyte Corporation (NASDAQ:INCY)

Last Updated on 2/24/2017 by Staff